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In skeletal muscle, dystroglycan (DG) is the central component of the dystrophin-glycoprotein complex (DGC), a multimeric
protein complex that ensures a strong mechanical link between the extracellular matrix and the cytoskeleton. Several muscular
dystrophies arise from mutations hitting most of the components of the DGC. Mutations within the DG gene (DAG1) have been
recently associated with two forms of muscular dystrophy, one displaying a milder and one a more severe phenotype. This review
focuses specifically on the animal (murine and others)model systems that have been developed with the aim of directly engineering
DAG1 in order to study the DG function in skeletal muscle as well as in other tissues. In the last years, conditional animal models
overcoming the embryonic lethality of the DG knock-out in mouse have been generated and helped clarifying the crucial role of
DG in skeletal muscle, while an increasing number of studies on knock-in mice are aimed at understanding the contribution of
single amino acids to the stability of DG and to the possible development of muscular dystrophy.
1. Introduction
The extracellular matrix receptor dystroglycan (DG) is highly
expressed in skeletal muscle and in several developing and
adult tissues, typically in cell types that adjoin basement
membranes, such as epithelial and neural tissues [1–3].
DG is composed of two subunits, 𝛼- and 𝛽-DG, deriving
from a posttranslational cleavage of a single mRNA species
encoded by a single gene (DAG1) [4]. 𝛼-DG is an extracellular
protein characterized by an extensive and heterogeneous gly-
cosylation mainly concentrated within an elongated central
mucin-like region which separates two globular domains,
the N- and C-terminal domains [5]. 𝛼-DG binds with
high affinities to the LG domains-containing extracellular
proteins, such as laminin-𝛼2, perlecan, and agrin, and in turn
interacts noncovalently with the𝛽-subunit, a transmembrane
protein [6]. The cytosolic domain of 𝛽-DG is anchored to
actin through the interaction with dystrophin [7–9], and 𝛽-
DG also constitutes a scaffold for proteins involved in signal
transduction such as Gbr2 and ERK [10, 11].
In skeletal muscle, DG is the central component of
the dystrophin-glycoprotein complex (DGC), a multisubunit
protein complex which links the actin cytoskeleton to the
extracellular matrix [12] (Figure 1). Other members of the
DGC include transmembrane proteins such as sarcoglycans
and sarcospan and multiple cytoplasmic proteins, including
dystrobrevin and syntrophins.
The role of the DGC in muscle is to provide mechanical
reinforcement to the sarcolemma and tomaintainmembrane
integrity during cycles of contraction and relaxation. In fact,
mutations in any components of the DGC cause distinct
forms of muscular dystrophy [13]. In humans, mutations in
dystrophin lead toDuchenne andBeckermuscular dystrophy
[14], mutations in sarcoglycans cause limb-girdle muscular
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Figure 1: Schematic representation of the dystrophin-glycoprotein complex (DGC) in skeletal muscle.Thismultiprotein complex anchors the
extracellularmatrix (ECM) to actin and other components of the cytoskeleton. O-Mannosylated𝛼-DG is a central component of this complex
and serves as binding partner for a number of ECM proteins containing LG domains, such as laminin-211. 𝛽-DG is a transmembrane protein
and binds the actin cytoskeleton via the direct interaction with dystrophin. Other intracellular molecules being a part of, or associated with,
DGC are dystrobrevin, syntrophins, and neural nitric oxide synthase (nNOS).
dystrophy [15–19], and mutations in laminin-𝛼2 cause con-
genital muscular dystrophy [20]. Recently, mutations in
DAG1 have been reported in three patients, affecting DG
function by impairing glycosylation of 𝛼-DG or by presum-
ably disrupting the 𝛼/𝛽-DG binding interface [21–23].
Moreover, several mutations in 12 proteins involved in
the O-mannosyl-glycosylation pathway of 𝛼-DG have been
identified so far which lead to a variety of clinical symptoms,
including severe muscular dystrophy and abnormal central
nervous system development and function. These diseases
are defined as “secondary dystroglycanopathies” (for recent
reviews see [24, 25]).The defectiveO-mannosyl glycosylation
of 𝛼-DG impairs its multiple interactions with its extracel-
lular partners, eventually destabilizing the link between the
cytoskeleton and the extracellular matrix. Secondary loss
of 𝛼- and 𝛽-DG at the muscle membrane also occurs in
Duchenne andBeckermuscular dystrophies [26] and in some
forms of limb-girdle muscular dystrophy [18].
The recovery of DG glycosylation state via transgenic
overexpression of LARGE, a putative enzyme involved in
the first steps of the posttranslational processing of 𝛼-DG,
has been proposed as a therapeutic strategy for muscular
dystrophy [27], although with conflicting outcomes [28–30].
The recently emerging data on patients affected by
primary and secondary dystroglycanopathies reinforce the
notion that a correct expression and modification of DG are
crucial for muscle fibres stability and function. A relevant
amount of genetic engineering work has been carried out so
far on the DAG1 gene in several laboratories. This review will
be focused on the animalmodels generated to understand the
function of DG in skeletal muscle, as well as in other tissues,
and to better understand its involvement in neuromuscular
disorders (Tables 1 and 2).
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Table 1: DG mouse models characterized by a muscle and/or central nervous system phenotype.
Mouse model Musculardystrophy CNS involvement NMJs
Chimaeric mice [34] Progressive — Disorganized and disrupted
MCK-Cre/DG-null [38] Mild — Normal
GFAP-Cre/DG-null [45] — Neuronal migration errors, brainmalformation —
MORE-DG-null [38, 39] Severe
Neuronal migration errors, brain
malformations, and ocular defects (WWS
phenotype)
—
Nestin-Cre/DG-null [47] and
Crx-Cre/DG-null [50] — Abnormal retinal physiology —
DGT192M/DGT192M [21] Mild Some neurological impairments Compromised
DGY890F/Y890F [56] Normal Normal Normal
DGY890F/Y890F/mdx [56] Ameliorated — Ameliorated
DGWToverexpression [40] Normal Normal 25% smaller than normalbut only 1% are aberrant
DGWToverexpression/mdx [40] Not ameliorated — Not ameliorated
DGS654Aoverexpression [63] Mild — Compromised
DGΔ𝛽cyt/Δ𝛽cyt [47] — Mild effects in the retina —
—: not analysed.
Table 2: Mouse models in which DG was targeted in tissues other than skeletal muscle and brain and additional DG animal models with
muscle and central nervous system defects.
Animal model Phenotype
Kidney specific DG knock-out mouse (podocin-Cre/DG-null,
Pax2-Cre/DG-null, Pax3-Cre/DG-null, HoxB7-Cre/DG-null) [64] Normal
Schwann cells specific DG knock-out mouse (P0-Cre/DG-null)
[66] Severe neurological dysfunctions
DG knock-out in Caenorhabditis elegans [68] Defects in gonad and vulval epithelium and in motoneurons
RNAi knock-out of DG in Drosophila melanogaster [73, 74] Muscle degeneration and neuronal defects
Inhibition of DG translation viamorpholino antisense in zebrafish
[78] Muscle defects
Zebrafish patchytail [79] Dystrophic muscles, ocular and central nervous system defects
Zebrafish dag1hu3072 [81] Muscular dystrophy
Inhibition of DG translation viamorpholino antisense in Xenopus
laevis [82–86]
Defects in the somitogenesis, epidermal differentiation, the
retinal and renal developing
Overexpression of DG in Xenopus laevis embryos [86] Aberrant neuromuscular junctions
2. From Knock-Out Mice to
the Different Strategies to Circumvent
Embryonic Lethality
In 1997 theDGknock-outmousewas generated and analyzed
in Kevin Campbell’s Laboratory [31].The targeting vector was
designed to replace a portion of theDAG1 second coding exon
with the neo-cassette following homologous recombination.
DAG1-null allele resulted in a deletion in the exon including
the 3󸀠 splice acceptor site and a large portion of the coding
sequence of 𝛼-DG. Animals that were heterozygous for the
targeted allele appeared healthy and bred normally. Inter-
estingly, DG transcripts in skeletal muscle of heterozygous
mice were only 10–20% lower than those in wild-type mice,
suggesting a compensatory increase in the expression level
of the untargeted allele. Accordingly, DG protein levels in
skeletal muscle were also comparable between wild-type and
heterozygous animals. However, theDGknock-outwas lethal
for homozygousmice embryos that died at the embryonic day
6.5 because of the disorganization of Reichert’s membrane,
one of the first specialized extraembryonic basement mem-
branes.The absence of laminin receptor precluded the assem-
bly of laminin in a network and the distribution of laminin
and collagen-IV appeared patchy, suggesting a crucial role of
DG in the organization of the basementmembranes [31].This
conclusion was further confirmed by the molecular analyses
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of the embryoid bodies derived fromhomozygousDAG1-null
ES cells in which an ordered basement membrane failed to
form [32].
As DG is involved in the development of basement
membranes, it certainly is fundamental for normal human
development, and the failure to identify null mutations in
DAG1 linked to muscular dystrophies in humans is probably
due to early embryonic lethality of such mutations. Inter-
estingly, Frost et al. described a patient affected by a mild
myopathy with central nervous system involvement who was
heterozygous for a DNA deletion which included also the
DG gene [33]. In this patient, only 50–60% of native DG is
produced and correctly glycosylated thus showing a much
lower degree of compensation compared to the heterozygous
DG-null mouse. Although other genes present in the same
deleted region could account for the phenotype, this case
report suggests the possibility that the heterozygosis for DG-
null mutations (haploinsufficiency) could produce patholog-
ical consequences in humans. A substantial genetic screening
effort, carried out on an enlarged number of patients, would
be necessary for the identification of additional cases thatmay
be related to the haploinsufficiency of DG.
To circumvent the embryonic lethality of the DG knock-
out mouse, highly chimaeric mice, generated with ES cells
targeted for both DAG1 alleles, were generated [34]. In
chimaeric mice deficient in DG rescued from the embryonic
lethality, skeletal muscle differentiated normally but they
developed a progressive muscular dystrophy reminiscent in
many respects of that of mice with double mutations in
dystrophin and utrophin [35]. Significant differences in fibre
size, central nuclei, and connective tissue infiltration charac-
terized the skeletal muscle histology of DG-null chimaeric
mice that die at 13 months [34]. DG plays a crucial role also
in stabilizing acetylcholine receptors [36] and consequently
in chimaeric mice the neuromuscular junctions (NMJs)
were grossly disorganized and disrupted [34]. In the most
severely affectedmice, the heart appeared dilated and with an
extensive connective tissue hyperplasia. At the sarcolemma
of DG-null chimaeric mice the entire DGC complex was
disassembled, with dystrophin and sarcoglycans absent in
many fibres. However, laminin-𝛼2, perlecan, and agrin were
expressed at wild-type levels and the basement membrane
appeared organized in an ordered network. It is likely that,
in differentiated skeletal muscle, the expression of integrins
or other extracellular matrix receptors exert an important
compensatory effect in supporting the skeletal muscle differ-
entiation and basement membrane assembly [37]. However,
the DG-null chimaeric mice pointed out the central role of
DG in the maintenance of the DGC and muscle integrity.
An additional step forward in understanding the func-
tional role of DG in skeletal muscle came from the condi-
tional inactivation of skeletal muscle DG using the Cre-loxP
system under the muscle creatine kinase (MCK) promoter
[38].TheMCK-Cre/DG-null mice were viable and born with
the expected frequency; they developed muscular dystrophy
around 4–6 weeks of age but the phenotype became milder
with advanced age. As a matter of fact, satellite cells, which
had not been targeted by the Cre recombinase, supported the
muscle regeneration and formation of novel fibres expressing
DG and the other components of DGC. Moreover, in old
mice, muscle fibres appeared hypertrophic and larger, as
compared with controls and with the other mouse models
of muscular dystrophy. Like in chimaeric DG-null mice, also
in MCK-Cre/DG-null mice, laminin-𝛼2 was expressed and
the basement membrane was correctly assembled. However,
while in chimaeric DG-null mice the NMJs were disrupted,
in MCK-DG-null mice they were preserved.
In MORE-DG-null mice [38], the inactivation of DAG1
was driven by Cre recombinase under the control of the Mox
2 promoter enabling the targeting of DG in all tissues of
the embryo, while DG was still expressed in extraembryonic
membranes to circumvent embryonic lethality. MORE-DG-
null mice were significantly smaller than control littermates,
a majority of the mice died within 48 h after birth, and
the remaining mice typically failed to survive the fourth
postnatal week. In addition, MORE-DG-null mice exhibited
profound muscle weakness and muscular dystrophy was
present at birth, reminiscent of a secondary dystroglycanopa-
thy phenotype (see next paragraph) [39]. Consistent with the
results obtained with MCK-Cre/DG-null mice, MORE-DG-
null mice displayed severe impaired regeneration capacity
since satellite cells were also targeted by Cre recombinase
under the control of the Mox 2 promoter [38].
The phenotype observed in chimaeric and conditional
knock-out mice demonstrated the importance of DG for the
stability of the DGC and for the structural integrity of the
sarcolemma. However, the overexpression of DG in trans-
genicmice onto anmdx background did not inhibit muscular
dystrophy; on the contrary, it exacerbated the phenotype by
decreasing the utrophin and sarcoglycans expression at the
sarcolemma [40].
3. Conditional DG Knock-Out in the Brain
Recapitulates the Outcome of Secondary
Dystroglycanopathies
Fukuyama congenital muscular dystrophy (FCMD), muscle-
eye-brain disease (MEB), and Walker-Warburg syndrome
(WWS) are congenital muscular dystrophies (CMDs) with
associated developmental brain defects [41–43]. The genes
that are mutated in these disorders are those of the enzymes
involved in the O-mannosyl glycosylation of 𝛼-DG, in par-
ticular protein-O-mannosyl transferase 1 (POMT1), protein-
O-mannosyl transferase 2 (POMT2), protein-O-linked man-
nose beta 1,2-N-acetylglucosaminyltransferase (POMGnT1),
and fukutin, an enzyme indirectly implicated in a pathway
to further modify the phosphorylated O-linked mannose
located in the mucin-like domain of 𝛼-DG [44].
The conditional DG knock-out mouse in the brain was
produced, using the Cre-LoxPmethodology, in order to anal-
yse the function of DG in the central nervous system and to
demonstrate the role of DG in the brain malformations seen
in CMDs [45]. Brain-selective expression of Cre recombinase
was accomplished using a human glial fibrillary acid protein
(GFAP) promoter expressed as early as embryonic day 13.5.
GFAP-Cre/DG-null mice followed the expected Mendelian
distribution and were fertile.
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In the GFAP-Cre/DG-null mice cerebral cortex, DG was
not expressed in the astrocytes abutting the brain surface (glia
limitans) and cerebral microvessels, in radial glia and in a
subset of neurons that are the progeny of radial glia [45, 46].
Also the localization of dystrophin isoforms was impaired in
these cells. The basal lamina of the glia limitans that plays
a critical role for normal cortical development was severely
disrupted. The results were a number of brain structural
developmental defects similar to those seen in MEB, WWS,
and FCMD patients. The abnormalities of the glia limitans
permitted the overextended migration of neurons in the
developing brain, which is the most important diagnostic
feature of cobblestone lissencephaly observed in the most
severe cases of secondary dystroglycanopathy. Suchmice also
lacked the usual fissure between the brain’s hemispheres, a
characteristic of WWS, and suffered from an overabundance
of glia.
Despite the large similarities withCMDs,GFAP-Cre/DG-
null mice did not recapitulate the most severe characteristics
observed in the brain of patients affected by WWS. On the
contrary, the earlier suppression of DG expression inMORE-
DG-null mice (in which Cre recombinase under the control
of theMox 2 promoter operates at E7.5) was sufficient to cause
malformations that broadly resembled the clinical spectrum
ofWWS, including hydrocephalus and ocular malformations
with structural defects of both the anterior and posterior
chambers of the eye [39].
The DAG1 gene was targeted to generate other mouse
models for the detailed analysis of the role of DG in the
central nervous system and in the visual function. For
example, the following two novel DG mouse models were
created and analyzed by Satz and colleagues [47]: (1) the
conditional knock-out nestin-CRE/DG-nullmouse, in which
Cre recombinase was under the control of the rat nestin
enhancer expressed in neuroepithelial precursor cells and in
the retina as early as embryonic day 9.5 (further analysed
in [48, 49]) and (2) a knock-in mouse expressing a trun-
cated DG lacking the entire 𝛽-DG cytodomain (in which a
premature stop codon was inserted after Lys778 resulting in
the presence of only 4 amino acids in the cytodomain of
𝛽-DG). Surprisingly, according to the authors, a reasonable
number of knock-in mice were obtained [47]. It remains
unclear whether these mice would display some pathologic
effect in their skeletal muscle.
Moreover, Omori and colleagues developed a retinal
photoreceptor-specific DG conditional knock-out (Crx-
Cre/DG-null) mice, in order to analyze the role of DG
localized at the presynaptic elements of photoreceptor cells
[50].The results showed the crucial role of presynapticDG for
both the formation of proper photoreceptor ribbon synaptic
structures and normal retinal electrophysiology.
4. DG Knocking-In: A Powerful Tool to Dissect
the Role Played by Specific Amino Acids
4.1. DG𝑇190𝑀/DG𝑇190𝑀, the First Case of Primary Dystrogly-
canopathy. Thefirst case of a homozygousmissensemutation
in the DAG1 gene was described in a 16-year-old patient [21]
originally described as affected by a mild form of limb-
girdle muscular dystrophy associated with mental retarda-
tion but normal brain imaging (recently classified as limb-
girdle muscular dystrophy 2P [51]). Immunofluorescence
and immunoblot of muscle biopsies showed that 𝛼-DG
was hypoglycosylated and had a reduced affinity toward
laminin. The mutation (T192M), located within the RNA
binding protein-like domain of the 𝛼-DG N-terminus [52],
is supposed to reduce, via a mechanism that needs to be
fully elucidated yet, the binding between 𝛼-DG and the
glycosyltransferase LARGE, an interaction that is essential
for the posttranslational modification of 𝛼-DG and for the
DG’s laminin-binding activity [53]. Recently, a mild form of
muscular dystrophy characterized by hypoglycosylated𝛼-DG
was associated with the compound heterozygous missense
mutations (V74I and D111N) with both mutated sites located
within the N-terminal domain of 𝛼-DG and a pathological
molecular mechanism similar to the one described for the
T192M mutation was hypothesized [22].
A knock-in mouse was generated introducing the muta-
tion T192M (that inmouse corresponds to T190M) by homol-
ogous recombination [21]. Heterozygous mice were normal,
while homozygous knock-in mice presented abnormalities
consistent with those observed in the patient. Analysis of
muscle biopsies revealed hallmarks of muscular dystrophy,
such as centrally nucleated fibres, and a hypoglycosylated 𝛼-
DG with a decreased laminin-binding activity. The T190M
mutation interfered also with the organization of the NMJ.
Although no structural abnormality was evident in the brains
of the knock-in mice, these mice had abnormal hind limb
clasping, a phenotype common to mouse models featur-
ing neurologic impairment. Interestingly, in the heart, the
mutated 𝛼-DG still bound to laminin and no obvious signs
of any pathological abnormality were observed.
Recently, a novel homozygousmutation inDAG1has been
identified in a Libyan family with two siblings affected by a
dystroglycanopathy resembling a MEB-like condition [23].
The mutation (C669F) hits an amino acid already identified
as an important site for the interaction between 𝛼- and 𝛽-DG
and for the overall stability of the complex, but the knock-in
mouse model has not been generated yet [54, 55].
4.2. DG𝑌890𝐹/𝑌890𝐹/mdx. Although not directly linked to a
specific disease, a knock-in mouse hitting a tyrosine within
the cytodomain of 𝛽-DG represented a tool for dissecting the
role of the phosphorylation of DG in the skeletal muscle and
for testing novel therapeutic ideas [56].
In fact, previous studies suggested that tyrosine phospho-
rylation of DG at the site Y892 may be an important mech-
anism for modulating the association of DG with its cellular
binding partners dystrophin and utrophin andmay also work
as a signal for proteasome degradation of DG [57–59].
The knock-in mouse DGY890F/Y890F was generated using
homologous recombination in ES cells [56]. Both heterozy-
gous and homozygous DGY890F/Y890F mice appeared normal
and healthy. Skeletalmuscle analysis of knock-inmice did not
reveal any differences or abnormalities compared to the wild-
type mice.
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In order to assess whether the inhibition of tyrosine
phosphorylation in DG had any beneficial effect on dys-
trophic skeletalmuscle, DGY890F/Y890F/mdxmicewere further
generated [56]. Interestingly, the expression of Y890Fmutant
DG in anmdx background significantly improved themuscle
phenotype, reducing the number of centrally nucleated fibres
and the levels of creatine kinase. Moreover, also an improve-
ment in resistance to eccentric contraction-induced injury
was observed in DGY890F/Y890F/mdx mice. Changing a single
phosphorylation site in DG reinforced the DGC sarcolemma
localization preventing the proteasomedegradation ofDG. In
fact, the inhibition of tyrosine phosphorylation of DG inmdx
mice was sufficient to restore the sarcolemma localization
of DG, 𝛼-sarcoglycan, and sarcospan also in the absence of
dystrophin, while utrophin was confined at the NMJ [56].
Moreover, an increase in the plectin expression/localization
at the sarcolemma was also observed. Plectin is a cytolinker
protein that binds 𝛽-DG at different sites, thus providing
a stabilizing link between DG and the cytoskeleton [60].
It was already known that treatment with proteasomal
inhibitors improves the muscle pathophysiology in some
mouse models, such asmdxmice [61] or 𝑑𝑦3𝐾mice [62], and
in this context theDGY890F/Y890F/mdxmouse highlights novel
targets for therapeutic intervention.
5. Mice Overexpressing DG
The overexpression of multiple and randomly integrated
copies of the coding sequence of DG was obtained by
microinjection of a pBS-HSAvpA cDNA construct into fer-
tilized CB6 oocytes. Mice overexpressing wild-type DG were
normal compared to control [63]. Interestingly, transgenic
lines overexpressing DG mutated in the cleavage site S654
were also created in order to understand the role of the
posttranslational cleavage resulting in the production of the
two interacting subunits [63]. In the transgenic DGS654A mice
only the uncleaved DG precursor was correctly expressed,
while the expression of endogenous and processed DG was
inhibited. In DGS654A mice, most muscles were dystrophic
with increased levels of central nuclei. The lack of the DG
cleavage and the presence of muscular dystrophy corre-
late with altered glycosylation of 𝛼-DG. In addition, the
expression of dystrophin and 𝛼-sarcoglycan decreased, while
utrophin and laminin-𝛼5 were upregulated, probably as a
secondary effect of muscle regeneration. Aberrant NMJs
were observed in DGS654A mice, although also DGWT mice
occasionally showed fragmented NMJ [63].
6. Conditional DG Knock-Out Mice in Other
Tissues Compared to Skeletal Muscle
DG is also highly expressed in epithelia and in the periph-
eral nervous system (Table 2). To study the role of DG
in the kidney, different conditional knock-out mice were
created to selectively delete DG from podocytes, ureteric
bud, metanephric mesenchyme derivatives, and all renal
epithelial cells using the Cre-lox system under the control
of podocin, HoxB7, Pax-3, and Pax-2 promoters, respectively
[64]. Surprisingly, DG deletion from kidney resulted in
no aberrant phenotypes. Kidney formation and function
proceeded normally in the absence of DG and the only
detectable abnormality was a mild increase of the glomerular
basement membrane thickness. This observation was further
confirmed in chimaeric mice generated with fukutin-null
embryonic stem cells expressing a hypoglycosylated 𝛼-DG, in
which minor glomerular structure abnormalities were found
without functional renal defects [65]. These results suggest
that DG and its correct glycosylation may be important in
the maintenance of podocyte architecture and extracellular
matrix assembly; however, the presence of integrin 𝛼3𝛽1
as an additional laminin receptor and basement membrane
organizer in podocytes may preserve the structure and
functionality of the kidney [65]. Accordingly, there are no
reported renal dysfunctions in human patients with impaired
DG glycosylation.
To analyse the role of DG in peripheral nerves, DG
was disrupted selectively in Schwann cells using the P0
protein promoter and Cre-loxP technology [66]. The loss
of DG caused severe neurological dysfunctions, including
a slow nerve conduction. In P0-Cre/DG-null mice the
myelin sheaths around the nerves were structurally abnor-
mal and extended throughout the internodal segments.
The DG-interacting proteins, sarcospan, sarcoglycan, and 𝛼-
dystrobrevin, were lost from the membrane and laminin was
not deposited around the nerves. These findings point to the
crucial role of DG in myelin integrity and in node of Ranvier
structure and function [67].
7. Other Animal Models to Study
the DG Functions in Muscle and Central
Nervous System
DG and most of the members of DGC are highly conserved
in vertebrates, including fish, and invertebrates. Therefore,
DG offers a wide range of possible animal models aside from
mouse to understand the role of DG in the pathogenesis of
muscular dystrophies.
7.1. Caenorhabditis elegans. Interestingly, in Caenorhabditis
elegans,DG is expressed in epithelial and neuronal tissues but
not in muscle. Indeed, a deletion, cg121, that removes most of
the coding and some of the 3󸀠 untranslated region of DGN-
1 gene, resulted in viable but sterile animals, with neuronal
defects and normal muscles [68]. DGN-1 contains the N-
terminal immunoglobulin-like domain of vertebrate 𝛼-DG
and a shorter mucin-like region, while the 𝛼/𝛽 proteolytic
cleavage region and the residues involved in bindingWWand
SH3 domain-containing proteins such as dystrophin are all
missing [68].
7.2. Drosophila melanogaster. All known components of the
DGC are present in the fruit fly [69]. Several Drosophila
DG isoforms are generated via alternative splicing [70, 71].
Only one of these contains the full mucin-like domain,
characterized by significant levels of glycosylation, while DG
isoforms that lack the mucin-like domain are required to
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maintain polarity in the follicular epithelium, suggesting that
the isoforms can have different functional roles inDrosophila
[71]. Moreover, Drosophila DG is not cleaved in 𝛼- and 𝛽-
subunits but it is expressed as a single polypeptide [72].
Interestingly, muscle-specific RNAi-mediated knock-
down of DG, as well as of dystrophin isoforms, led to
age-dependent, progressive climbing deficits, severe muscle
degeneration in adult flies, and defects in neurons migration
and eye development [73]. Haines and colleagues, analysing
larvae carryingmutant alleles of DG, also established thatDG
is required in Drosophila larval muscles to maintain integrity
[74].
The similar defects observed in both flies and humans
make Drosophila an attractive model for further studies on
clarifying the role of the DGC. In particular, using the RNAi
knockdown mutants of DG, many genes had been identified
as possible regulatory genes of DG and dystrophin, such
as genes involved in muscle function and components of
Notch, TGF-𝛽, and EGFR signalling pathways [75]. Recently,
it was also shown that in Drosophila the expression level
of DG may be buffered in a homeostatic fashion via a
mechanism mediated by the miR-310s complex which acts
directly on the alternative DG 3󸀠-UTR [76]. Deficiencies
in the miR-310s complex resulted in cobblestone brain, a
phenotype reminiscent of human lissencephaly type II [76].
This evidence represents a seminal result, paving the way
for identifying similar regulation mechanisms also in higher
vertebrates and mammals.
7.3. Danio rerio. In recent years, Danio rerio (zebrafish)
has emerged as a powerful genetic tool to study muscle
diseases [77]. Disruption of DG translation using an anti-
sense morpholino oligonucleotide (MO) approach, led to the
destabilization of the embryos muscle, with loss of sarcomere
organisation and necrosis of the developing muscle [78]. The
NMJ and central nervous system appeared normal. The lack
of the DG protein impaired also the localization of dys-
trophin. Interestingly, in an ENU (N-ethyl-N-nitrosourea)
mutagenesis screen aimed at identifying genes responsible for
skeletal muscle disorders, a DG homozygousmutant, patchy-
tail, was found to show impaired locomotion behaviour,
dystrophic muscles and ocular and central nervous system
defects [79].The pointmutation resulted in amissense amino
acid change of valine to aspartic acid (V567D) within the Ig-
like domain in the C-terminal region of a-DG, leading to a
destabilization and degradation of the protein [79, 80]. The
absence of DG led to a reduced expression of dystrophin and
laminin-a2. The sarcolemma appeared grossly disorganized
and detached from the extracellular matrix. NMJs were
normal in patchytail fish, but severe abnormalities of brain
and eyes were observed and the embryos did not survive
more than 10 days post fertilization. This case represents
so far the first case in which a single point mutation is
able to induce the complete depletion of DG from tissues,
highlighting the importance that even single aminoacidsmay
have for the stability and/or folding pathway of the DG
precursor [56, 80]. An additional loss of function mutation
was identified in a zebrafish affected by muscular dystrophy
(dag1hu3072) due to a nonsense mutation (R398>Stop) within
the mucin-like region of a-DG, causing the complete loss
of DG [81]. The absence of DG led to the dislocation of
dystrophin and to muscle fibre detachment, followed by
disruption of sarcolemma integrity.
7.4. Xenopus laevis. The possible DG functions in different
tissues ofXenopus laeviswere analysed using the morpholino
knock-out approach. It was shown that, during Xenopus
development, DG is important for the somitogenesis and
that the interaction between DG and the extracellular matrix
is indispensable for the alignment of the myoblasts in the
somites [82]. The loss of DG influenced the epidermal
differentiation in the retinal and renal development [83–85].
Moreover, the injection of rabbit DG RNA into Xenopus
embryos produced an overexpression of DG that altered the
acetylcholine receptors aggregation and the NMJ structure
[86].
8. Perspectives
Starting from the 1997 knock-out mouse [31], during the last
17 years, an impressive amount of work has been carried out
already on DG at the genetic level. It is likely to expect in
the next few years a further increase both in the number of
patients/families identified who carry mutations specifically
within the DAG1 gene and in the number of animal genetic
models that will be generated and analyzed. In particular, it
could be particularly interesting to focus on the 3󸀠 region of
DAG1, corresponding to the 𝛼/𝛽-DG interface, the genetic
clinical screenings carried out on still unassigned cases of
myopathy presenting with symptoms that may suggest the
presence of a dystroglycanopathy. In this specific and very
small region (that could be therefore analyzed inexpensively)
in fact, mutations have been found to grossly affect the
stability and the maturation of the complex, in zebrafish as
well as in human patients [23, 79, 81].
Via such comparative studies, a full circle will be com-
pleted in the elucidation of the function(s) of DG in muscle
and nonmuscle tissues. Moreover, the genetic data on human
patients and the generation of novel animal models will cer-
tainly boost the research on potential therapeutic approaches
for human muscular dystrophies.
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